Af­ter Roundup de­ba­cle, Bay­er's share­hold­ers vote against man­age­ment pay scheme

As Bay­er looks to set­tle lit­i­ga­tion sur­round­ing claims that its weed­killer Roundup caus­es can­cer, share­hold­ers vot­ed on Fri­day to rep­ri­mand the man­age­ment team for its pay scheme, say­ing that it didn’t rep­re­sent the bur­den of the lit­i­ga­tion.

Near­ly 75% of share­hold­ers vot­ed against the ap­proval of the ex­ec­u­tive board’s com­pen­sa­tion. The vote came af­ter ad­vi­so­ry firm Glass Lewis wrote that it had prob­lems with how Bay­er ad­just­ed a man­age­ment pay­out that re­lies on group cash flow to com­pen­sate for the mon­ey lost to lit­i­ga­tion. That’s a stark dif­fer­ence from last year, when the group got an 82% ap­proval rate for its work in 2021.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER